Moreover, IMD can reduce the levels of fasting blood glucose (FBG), insulin, free fatty acid, triglycerides, and total cholesterol, thereby improving metabolic syndromes like obesity and insulin resistance in T1DM rats, T2DM mice, hyperhomocysteinemia mice, and ApoE−/− atherosclerosis mice [39,40,41,42]. This evidence concerns the gene APOE and obesity due to melanocortin 4 receptor deficiency.